GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (NAS:ZYME) » Definitions » Cyclically Adjusted PB Ratio

Zymeworks (Zymeworks) Cyclically Adjusted PB Ratio : 1.41 (As of Apr. 29, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Zymeworks Cyclically Adjusted PB Ratio?

As of today (2024-04-29), Zymeworks's current share price is $8.26. Zymeworks's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec23 was $5.87. Zymeworks's Cyclically Adjusted PB Ratio for today is 1.41.

The historical rank and industry rank for Zymeworks's Cyclically Adjusted PB Ratio or its related term are showing as below:

ZYME' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.41   Med: 1.8   Max: 2.13
Current: 1.41

During the past 10 years, Zymeworks's highest Cyclically Adjusted PB Ratio was 2.13. The lowest was 1.41. And the median was 1.80.

ZYME's Cyclically Adjusted PB Ratio is ranked better than
56.01% of 641 companies
in the Biotechnology industry
Industry Median: 1.72 vs ZYME: 1.41

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Zymeworks's adjusted book value per share data of for the fiscal year that ended in Dec23 was $6.629. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $5.87 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


Zymeworks Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Zymeworks's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zymeworks Cyclically Adjusted PB Ratio Chart

Zymeworks Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.77

Zymeworks Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 1.77

Competitive Comparison of Zymeworks's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Zymeworks's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zymeworks's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zymeworks's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Zymeworks's Cyclically Adjusted PB Ratio falls into.



Zymeworks Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Zymeworks's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=8.26/5.87
=1.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zymeworks's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec23 is calculated as:

For example, Zymeworks's adjusted Book Value per Share data for the fiscal year that ended in Dec23 was:

Adj_Book=Book Value per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=6.629/129.4194*129.4194
=6.629

Current CPI (Dec23) = 129.4194.

Zymeworks Annual Data

Book Value per Share CPI Adj_Book
201412 0.000 99.070 0.000
201512 0.919 99.792 1.192
201612 0.457 101.863 0.581
201712 4.576 104.011 5.694
201812 5.644 105.998 6.891
201912 6.210 108.420 7.413
202012 8.904 109.897 10.486
202112 5.341 117.630 5.876
202212 7.817 125.222 8.079
202312 6.629 129.419 6.629

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zymeworks  (NAS:ZYME) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Zymeworks Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Zymeworks's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zymeworks (Zymeworks) Business Description

Industry
Traded in Other Exchanges
Address
108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Executives
Paul Andrew Moore officer: Chief Scientific Officer 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Christopher Astle officer: SVP & Chief Financial Officer 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Kenneth Galbraith director, officer: Chair & CEO OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Carlos Campoy director 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Miller Derek John Michael director 108 PATRIOT DRIVE, SUITE A, 1385 WEST 8TH AVENUE, SUITE 540, MIDDLETOWN DE 19709
Neil A Klompas officer: President & COO 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Lota S. Zoth director 334 CR 692, BUFFALO GAP TX 79508
Troy Cox director C/O FOUNDATION MEDICINE, INC., C/O FOUNDATION MEDICINE, INC., 150 SECON, CAMBRIDGE MA 02141
Kenneth J. Hillan director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Hollings Renton director
Kelvin Neu director 860 WASHINGTON STREET, 10TH FLOOR, NEW YORK NY 10014
Natalie Sacks director C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Susan Mahony director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Neil Josephson officer: Chief Medical Officer 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4

Zymeworks (Zymeworks) Headlines